"rucaparib" meaning in English

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "rucaparib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Drugs",
          "orig": "en:Drugs",
          "parents": [
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              121,
              130
            ]
          ],
          "ref": "2015 October 28, “Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma”, in PLOS ONE, →DOI:",
          "text": "Niraparib was selected because it was the only PARPi in clinical trials with temozolomide at the time of this study, and rucaparib and BMN-673 were selected because they are potent PARP trappers.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A drug being developed as a cancer treatment."
      ],
      "id": "en-rucaparib-en-noun-iTU0fFkr",
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "cancer",
          "cancer"
        ],
        [
          "treatment",
          "treatment"
        ]
      ],
      "tags": [
        "uncountable"
      ]
    }
  ],
  "word": "rucaparib"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "rucaparib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Drugs"
      ],
      "examples": [
        {
          "bold_text_offsets": [
            [
              121,
              130
            ]
          ],
          "ref": "2015 October 28, “Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma”, in PLOS ONE, →DOI:",
          "text": "Niraparib was selected because it was the only PARPi in clinical trials with temozolomide at the time of this study, and rucaparib and BMN-673 were selected because they are potent PARP trappers.",
          "type": "quote"
        }
      ],
      "glosses": [
        "A drug being developed as a cancer treatment."
      ],
      "links": [
        [
          "drug",
          "drug"
        ],
        [
          "cancer",
          "cancer"
        ],
        [
          "treatment",
          "treatment"
        ]
      ],
      "tags": [
        "uncountable"
      ]
    }
  ],
  "word": "rucaparib"
}